Onderzoeker
Stefan Goemaere
- Disciplines:Endocrinologie en metabole ziekten, Pediatrie en neonatologie, Verpleegkunde
Affiliaties
- Vakgroep Inwendige ziekten en Pediatrie (Departement)
Lid
Vanaf1 okt 2018 → Heden - Vakgroep Inwendige ziekten (Departement)
Lid
Vanaf7 okt 2013 → 30 sep 2014
Publicaties
1 - 10 van 46
- Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density : a randomized, double-blind, phase 2, parallel group study(2018)
Auteurs: Michael R McClung, Jacques P Brown, Adolfo Diez-Perez, Heinrich Resch, John Caminis, Paul Meisner, Michael A Bolognese, Stefan Goemaere, Henry G Bone, Jose R Zanchetta, et al.
Pagina's: 1397 - 1406 - A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis(2018)
Auteurs: E Michael Lewiecki, Tomasz Blicharski, Stefan Goemaere, Kurt Lippuner, Paul D Meisner, Paul D Miller, Akimitsu Miyauchi, Judy Maddox, Li Chen, Stephane Horlait
Pagina's: 3183 - 3193 - BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta : results of a randomized phase 2a trial(2017)
Auteurs: Francis H Glorieux, Jean-Pierre Devogelaer, Michaela Durigova, Stefan Goemaere, Sarah Hemsley, Franz Jakob, Uwe Junker, Jon Ruckle, Lothar Seefried, Peter J Winkle
Pagina's: 1496 - 1504 - Patients' preferences for anti-osteoporosis drug treatment : a cross-European discrete choice experiment(2017)
Auteurs: Mickael Hiligsmann, Benedict G Dellaert, Carmen D Dirksen, Verity Watson, Sandrine Bours, Stefan Goemaere, Jean-Yves Reginster, Christian Roux, Bernie McGowan, Carmel Silke, et al.
Pagina's: 1167 - 1176 - Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass(2017)
Auteurs: Harry K Genant, Klaus Engelke, Michael A Bolognese, Carlos Mautalen, Jacques P Brown, Chris Recknor, Stefan Goemaere, Thomas Fuerst, Yu-Ching Yang, Andreas Grauer, et al.
Pagina's: 181 - 187 - Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy : a randomised, open-label, phase 3 trial(2017)
Auteurs: Bente L Langdahl, Cesar Libanati, Daria B Crittenden, Michael A Bolognese, Jacques P Brown, Nadia S Daizadeh, Eva Dokoupilova, Klaus Engelke, Joel S Finkelstein, Harry K Genant, et al.
Pagina's: 1585 - 1594 - Skeletal health in breast cancer survivors(2017)
Auteurs: Olivier Bruyère, Pierre Bergmann, Etienne Cavalier, Evelien Gielen, Stefan Goemaere, Jean Kaufman, Serge Rozenberg, Jean-Jacques Body
Pagina's: 78 - 82 - A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture(2015)
Auteurs: Santiago Palacios, Stuart L Silverman, Tobie J de Villiers, Amy B Levine, Stefan Goemaere, Jacques P Brown, Fiorenzo De Cicco Nardone, Robert Williams, Teresa L Hines, Sebastian Mirkin, et al.
Pagina's: 806 - 813 - Effective secondary fracture prevention: implementation of a global benchmarking of clinical quality using the IOF Capture the Fracture® Best Practice Framework tool(2015)
Auteurs: MK Javaid, C Kyer, PJ Mitchell, J Chana, C Moss, MH Edwards, AR McLellan, J Stenmark, DD Pierroz, MC Schneider, et al.
Pagina's: 2573 - 2578 - Are patients' preferences transferable between countries?: a cross-European discrete-choice experiment to elicit patients' preferences for osteoporosis drug treatment(2014)Volume: 17
Auteurs: M Hiligsmann, B Dellaert, C Dirksen, T Van der Weijden, V Watson, Stefan Goemaere, JY Reginster, S Bours, C Roux, B McGowan, et al.
Pagina's: A385 - A385